Full Text View
Tabular View
Study Results
Related Studies
Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat
This study has been completed.
Study NCT00402987   Information provided by Pfizer

First Received on November 21, 2006.   Last Updated on June 8, 2009   History of Changes
Results First Received: November 14, 2008  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Pharyngitis
Interventions: Drug: celecoxib
Drug: celecoxib followed by placebo
Drug: placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
1 center in the United States.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Celecoxib 50mg/50mg Dose 1 celecoxib 50 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
Celecoxib 100mg/Placebo Dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 placebo
Celecoxib 100mg/50mg Dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
Placebo Dose 1 placebo followed 6-12 hours later by dose 2 placebo

Participant Flow:   Overall Study
    Celecoxib 50mg/50mg     Celecoxib 100mg/Placebo     Celecoxib 100mg/50mg     Placebo  
STARTED     90     45     45     89  
COMPLETED     90     45     44     89  
NOT COMPLETED     0     0     1     0  
Lack of Efficacy                 0                 0                 1                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Celecoxib 50mg/50mg Dose 1 celecoxib 50 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
Celecoxib 100mg/Placebo Dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 placebo
Celecoxib 100mg/50mg Dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
Placebo Dose 1 placebo followed 6-12 hours later by dose 2 placebo

Baseline Measures
    Celecoxib 50mg/50mg     Celecoxib 100mg/Placebo     Celecoxib 100mg/50mg     Placebo     Total  
Number of Participants  
[units: participants]
 		  90     45     45     89     269  
Age  
[units: years]
Mean ± Standard Deviation 		  19.5  ± 1.3     19.6  ± 1.4     19.9  ± 2.3     19.3  ± 1.4     19.5  ± 1.5  
Gender  
[units: participants]
 		         
Female     55     25     15     49     144  
Male     35     20     30     40     125  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Sum of Sore Throat Pain Intensity Difference (SPID2) on Swallowing at 2 Hours Post-First Dose   [ Time Frame: 2 hours Post-First Dose ]
  Show Outcome Measure 1

2.  Secondary:   Sore Throat Pain Intensity Difference (PID) Within 6 Hours Post-First Dose   [ Time Frame: Within First 6 hours Post-First Dose ]
  Show Outcome Measure 2

3.  Secondary:   Sore Throat Pain Intensity Difference (PID) From 7 to 24 Hours Post-First Dose   [ Time Frame: 7 to 24 hours ]
  Show Outcome Measure 3

4.  Secondary:   Sum of Sore Throat Pain Intensity Difference (SPID) Within 6 Hours Post-First Dose   [ Time Frame: up to 6 hours ]
  Show Outcome Measure 4

5.  Secondary:   Sum of Sore Throat Pain Intensity Difference (SPID) From 7 to 24 Hours Post-First Dose   [ Time Frame: 7 to 24 hours ]
  Show Outcome Measure 5

6.  Secondary:   Sore Throat Relief Rating Scale (STRRS) Within 6 Hours Post-First Dose   [ Time Frame: within the first 6 hours ]
  Show Outcome Measure 6

7.  Secondary:   Sore Throat Relief Rating Scale (STRRS) From 7 to 24 Hours Post-First Dose   [ Time Frame: 7 to 24 hours ]
  Show Outcome Measure 7

8.  Secondary:   Sore Throat Relief Rating Scale (STRRS) - ‘Moderate Relief’ at 6 Hours Post-First Dose   [ Time Frame: at 6 hours ]
  Show Outcome Measure 8

9.  Secondary:   Sore Throat Relief Rating Scale (STRRS) - ‘Moderate Relief’ at 12 Hours Post-First Dose   [ Time Frame: 12 hours ]
  Show Outcome Measure 9

10.  Secondary:   Time to Perceptible Pain Relief   [ Time Frame: Within 2 Hours Post-First Dose ]
  Show Outcome Measure 10

11.  Secondary:   Time to Meaningful Pain Relief   [ Time Frame: Within 2 Hours Post-First Dose ]
  Show Outcome Measure 11

12.  Secondary:   Time to Onset of Analgesia   [ Time Frame: Within 2 Hours Post-First Dose ]
  Show Outcome Measure 12

13.  Secondary:   Patient’s Global Evaluation of Study Medication at 6 Hours Post-First Dose   [ Time Frame: 6 Hours Post-First Dose ]
  Show Outcome Measure 13

14.  Secondary:   Patient’s Global Evaluation of Study Medication at 12 and 24 Hours Post-First Dose   [ Time Frame: 12 and 24 hours Post-First Dose ]
  Show Outcome Measure 14

15.  Other Pre-specified:   Throat Soreness Scale (TSS) Difference Within 6 Hours Post-First Dose   [ Time Frame: Within first 6 hours post-first dose ]
  Show Outcome Measure 15

16.  Other Pre-specified:   Throat Soreness Scale (TSS) Difference From 7 to 24 Hours Post-First Dose   [ Time Frame: 7 to 24 hours post-first dose ]
  Show Outcome Measure 16

17.  Other Pre-specified:   Sore Throat Pain Intensity Difference (SPID2) as Measured by Throat Soreness Scale (TSS) at 2 Hours Post-First Dose   [ Time Frame: 2 hour period Post-First Dose ]
  Show Outcome Measure 17

18.  Other Pre-specified:   Sum of Throat Soreness Difference as Measured by Throat Soreness Scale (TSS) Within 6 Hours Post-First Dose   [ Time Frame: Within 6 hours Post-First Dose ]
  Show Outcome Measure 18

19.  Other Pre-specified:   Sum of Throat Soreness Difference as Measured by Throat Soreness Scale (TSS) From 7 to 24 Hours Post-First Dose   [ Time Frame: 7 to 24 hours Post-First Dose ]
  Show Outcome Measure 19

20.  Other Pre-specified:   Difficulty Swallowing Difference as Measured by Difficulty Swallowing Scale (DSS) Within 6 Hours Post-First Dose   [ Time Frame: Within 6 hours Post-First Dose ]
  Show Outcome Measure 20

21.  Other Pre-specified:   Difficulty Swallowing Difference as Measured by Difficulty Swallowing Scale (DSS) From 7 to 24 Hours Post-First Dose   [ Time Frame: 7 to 24 hours Post-First Dose ]
  Show Outcome Measure 21

22.  Other Pre-specified:   Sum of Sore Throat Pain Intensity Difference (SPID2) as Measured by Difficulty Swallowing Scale (DSS) at 2 Hours Post-First Dose   [ Time Frame: Over 2 hour Period Post-First Dose ]
  Show Outcome Measure 22

23.  Other Pre-specified:   Sum of Difficulty Swallowing Difference as Measured by Difficulty Swallowing Scale (DSS) Within 6 Hours Post-First Dose   [ Time Frame: Within 6 hours Post-First Dose ]
  Show Outcome Measure 23

24.  Other Pre-specified:   Sum of Difficulty Swallowing Difference as Measured by Difficulty Swallowing Scale (DSS) From 7 to 24 Hours Post-First Dose   [ Time Frame: 7 to 24 hours Post-First Dose ]
  Show Outcome Measure 24

25.  Other Pre-specified:   Difficulty Swallowing Scale (DSS) Difference at Least 50% Gone at 6 Hours Post-First Dose   [ Time Frame: At 6 hours ]
  Show Outcome Measure 25

26.  Other Pre-specified:   Difficulty Swallowing Scale (DSS) Difference at Least 50% Gone at 12 Hours Post-First Dose   [ Time Frame: At 12 Hours ]
  Show Outcome Measure 26

27.  Other Pre-specified:   Total Pain Relief (TOTPAR) at 2 and 6 Hours Post-First Dose   [ Time Frame: 2 and 6 hours Post-First Dose ]
  Show Outcome Measure 27

28.  Other Pre-specified:   Total Pain Relief (TOTPAR) at 12 and 24 Hours Post-First Dose   [ Time Frame: 12 and 24 hours Post-First Dose ]
  Show Outcome Measure 28

29.  Other Pre-specified:   Subjects With >= 50% Total Pain Relief (TOTPAR) at 6 Hours Post-First Dose   [ Time Frame: 6 hours Post-First Dose ]
  Show Outcome Measure 29

30.  Other Pre-specified:   Subjects With >= 50% Total Pain Relief (TOTPAR) at 12 Hours Post-First Dose   [ Time Frame: 12 hours Post-First Dose ]
  Show Outcome Measure 30

31.  Other Pre-specified:   Number Needed to Treat (NNT) to Achieve at Least 50% of Maximum Total Pain Relief (TOTPAR) at 6 Hours Post-First Dose   [ Time Frame: 6 hours Post-First Dose ]
  Show Outcome Measure 31

32.  Other Pre-specified:   Number Needed to Treat (NNT) to Achieve at Least 50% of Maximum Total Pain Relief (TOTPAR) at 12 Hours Post-First Dose   [ Time Frame: 12 hours Post-First Dose ]
  Show Outcome Measure 32

33.  Other Pre-specified:   Subjects With Sore Throat Pain at Least 35% Gone and at Least 50% Gone at 2 and 6 Hours Post-First Dose   [ Time Frame: 2 and 6 hours Post-First Dose ]
  Show Outcome Measure 33

34.  Other Pre-specified:   Subjects With Sore Throat Pain at Least 35% Gone and at Least 50% Gone at 12 Hours Post-First Dose   [ Time Frame: 12 hours Post-First Dose ]
  Show Outcome Measure 34

35.  Other Pre-specified:   Subjects Who Achieved Their Own Level of 'Meaningful Relief' and 'Much Improvement' at 2 and 6 Hours Post-First Dose   [ Time Frame: 2 and 6 hours Post-First Dose ]
  Show Outcome Measure 35

36.  Other Pre-specified:   Subjects Who Achieved Their Own Level of 'Meaningful Relief' and 'Much Improvement' at 12 Hours Post-First Dose   [ Time Frame: 12 hours Post-First Dose ]
  Show Outcome Measure 36

37.  Other Pre-specified:   Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Who Had Perceptible Relief Onset Time Within 1 Hour   [ Time Frame: Within 6 hours Post-First Dose ]
  Show Outcome Measure 37

38.  Other Pre-specified:   Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Who Still Had Perceptible Relief at 12 and 24 Hours Post-First Dose   [ Time Frame: 12 and 24 hours Post-First Dose ]
  Show Outcome Measure 38

39.  Other Pre-specified:   Median Onset Time of First Perceptible Relief in Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Post-First Dose   [ Time Frame: 24 Hours ]
  Show Outcome Measure 39

40.  Other Pre-specified:   Median Offset Time of No Perceptible Relief in Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Post-First Dose   [ Time Frame: 24 Hours ]
  Show Outcome Measure 40

41.  Other Pre-specified:   Treatment Failures on STRRS Questionnaire   [ Time Frame: 24 hours Post-First Dose ]
  Show Outcome Measure 41

42.  Other Pre-specified:   Subjects Taking Rescue Medication   [ Time Frame: Within 24 hours Post-First Dose ]
  Show Outcome Measure 42

43.  Other Pre-specified:   Treatment Satisfaction Questionnaire for Medication (TSQM vII)   [ Time Frame: 24 hours or immediately prior to taking rescue medication ]
  Show Outcome Measure 43

44.  Other Pre-specified:   First Perceptible Relief   [ Time Frame: up to 24 hours ]
  Show Outcome Measure 44

45.  Other Pre-specified:   No Perceptible Relief   [ Time Frame: up to 24 hours ]
  Show Outcome Measure 45


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Pfizer ClinicalTrials.gov Call Center
Organization: Pfizer, Inc.
phone: 1-800-718-1021
e-mail: ClinicalTrials.govCallCenter@pfizer.com


No publications provided


Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00402987     History of Changes
Other Study ID Numbers: A3191334
Study First Received: November 21, 2006
Results First Received: November 14, 2008
Last Updated: June 8, 2009
Health Authority: United States: Food and Drug Administration





Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services